Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Sodium dichloroacetate by Saol Therapeutics for Neurometabolic Disease: Likelihood of Approval
Sodium dichloroacetate is under clinical development by Saol Therapeutics and currently in Phase III for Neurometabolic Disease. According to GlobalData,...